
A clinical trial of Xibrom (bromfenac sodium ophthalmic solution; ISTA Pharmaceuticals) has demonstrated equivalence of end-point achievement between the 0.18% and the 0.09% formulations, according to topline results published by ISTA Pharmaceuticals.